Soluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucoma
Primary open angle glaucoma (POAG) is a leading cause of blindness worldwide. The molecular signaling involved in the pathogenesis of POAG remains unknown. Here, we report that mice lacking the α1 subunit of the nitric oxide receptor soluble guanylate cyclase represent a novel and translatable anima...
Saved in:
Published in | PloS one Vol. 8; no. 3; p. e60156 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
20.03.2013
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Primary open angle glaucoma (POAG) is a leading cause of blindness worldwide. The molecular signaling involved in the pathogenesis of POAG remains unknown. Here, we report that mice lacking the α1 subunit of the nitric oxide receptor soluble guanylate cyclase represent a novel and translatable animal model of POAG, characterized by thinning of the retinal nerve fiber layer and loss of optic nerve axons in the context of an open iridocorneal angle. The optic neuropathy associated with soluble guanylate cyclase α1-deficiency was accompanied by modestly increased intraocular pressure and retinal vascular dysfunction. Moreover, data from a candidate gene association study suggests that a variant in the locus containing the genes encoding for the α1 and β1 subunits of soluble guanylate cyclase is associated with POAG in patients presenting with initial paracentral vision loss, a disease subtype thought to be associated with vascular dysregulation. These findings provide new insights into the pathogenesis and genetics of POAG and suggest new therapeutic strategies for POAG. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: Peter Brouckaert: The Flemish Institute for Biotechnology receives a fee from a nonexclusive license of sGCα1−/− mice to the pharmaceutical industry. This study was partly funded by an Allergan Horizon grant. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. Performed statistical analyses: RM. Conceived and designed the experiments: ESB YCK CA MSC CPL HG DJR PB JLW MSG LRP KDB BRK. Performed the experiments: ESB YCK CA SRH AJ LTT RR AG MC EA RETT DJO NdW BY RT DN MSC SJL JHK MSG. Analyzed the data: ESB YCK CA AJ LTT RR AG MC PA RT DN MSC SJL JHK HG JLW MSG LRP KDB BRK. Contributed reagents/materials/analysis tools: PB. Wrote the paper: ESB RM PA MSC HG DJR PB JLW MSG LRP KDB BRK. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0060156 |